

Date and Time: *Tuesday 10th September 2013, 10:00-16:00*

Minutes: Final

Atrial Fibrillation Guideline Development Group Meeting

Place: Boardroom, National Clinical Guideline Centre (NCGC), 180 Great Portland Street, London W1W 5QZ

Present: Campbell Cowan (Chair) (CC)
John Campbell (JC)
V-Lin Cheong (VC)
George Chung (GC)
Matthew Fay (MF)
David Fitzmaurice (DF)
Gregory Lip (GL)
Clifford Mann (CM)
Eileen Porter (EP)
Suzannah Power (SP)
Richard Schilling (RS)

In attendance:

NICE Staff:	Clare Jones (CJ) Jill Parnham (JP) Vicki Pollit (VP) Maggie Westby (MW)	Present for notes 1-2
NICE attendee 1	Caroline Kier (CK)	

Observers:

None		
------	--	--

Notes

1. CC welcomed the group to the ninth meeting of this GDG. Apologies were received from NM and RSc. The Chair asked all GDG members to declare any relevant conflicts of interest.

MF declared a non-personal pecuniary interest; he undertook an AF clinic with Apodi for which Westcliffe Medical Partnership was paid for his time (July 2013). He declared a personal non-pecuniary interest; he was appointed as a medical advisor to Anticoagulation Europe (August 2013). He has been supporting the National Stroke Association Aphasia Campaign, with pieces written for the GP newspapers. He has written a piece for Pulse Magazine on HASBLED for which he was not paid.

RS declared a personal non-pecuniary interest; he received an economy flight to the European Cardiac Society AGM by Daiichi Sankyo.

The remaining GDG members and NCGC technical team declared no changes above previously declared interests. GL withdrew from the stroke risk debate of draft recommendations.

The minutes of the last meeting of this group were agreed as a true and accurate account of the meeting.

2. **Clinical and cost effectiveness evidence on stroke risk scores:**
MW presented the clinical evidence on stroke risk scores. There was no cost effectiveness evidence for this review.
3. **Clinical and cost effectiveness evidence on patient information review:**
CJ and VP presented the clinical and cost effectiveness evidence on patient education.
4. **Guideline re-runs:**
CJ and VP presented the clinical and cost effectiveness evidence from the re-run searches.
5. **Research recommendations and Key Priorities for Implementation (KPIs):**
CJ gave a presentation on research recommendations and KPIs
6. **Any other business**
There was no other business.

Date, time and venue of the next meeting

7. Wednesday 11th September 2013, 10:-16:00 Boardroom, NCGC offices, 180 Great Portland Street, London, W1W 5QZ.